AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
admin 15th November 2017 Uncategorised 0Ovarian cancer treatment has changed dramatically, and with several new drugs now duking it out in that market, the battle for share is changing, too. If recent numbers—and a new doctor survey—are any indication, Tesaro’s Zejula is in the lead. But that could change.
More: AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Source: fierce